Cantitate/Preț
Produs

Disease-modifying Therapy in Vasculitides: Progress in Inflammation Research

Editat de Cees G.M. Kallenberg, Jan W. Cohen Tervaert
en Limba Engleză Hardback – aug 2001
Especially the past two decades have seen renewed interest in the vasculitides. In this volume an international expert group presents the current state of knowledge and concentrates on principles of immune modulating therapy. Drawing from their work in rheumatology, nephrology, internal medicine, connective tissue disease and clinical immunology, they present new concepts in classificiation, diagnosis and pathophysiology of the vasculitides. Evidence from experimental and clinical trials is reviewed, as well as the outlook for further research.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 106797 lei  43-57 zile
  Birkhäuser Basel – 23 oct 2012 106797 lei  43-57 zile
Hardback (1) 107475 lei  43-57 zile
  Birkhäuser Basel – aug 2001 107475 lei  43-57 zile

Din seria Progress in Inflammation Research

Preț: 107475 lei

Preț vechi: 113131 lei
-5% Nou

Puncte Express: 1612

Preț estimativ în valută:
20569 21365$ 17085£

Carte tipărită la comandă

Livrare economică 03-17 februarie 25

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783764361471
ISBN-10: 3764361476
Pagini: 206
Ilustrații: IX, 206 p.
Dimensiuni: 155 x 235 x 17 mm
Greutate: 0.49 kg
Ediția:2001
Editura: Birkhäuser Basel
Colecția Birkhäuser
Seria Progress in Inflammation Research

Locul publicării:Basel, Switzerland

Public țintă

Research

Cuprins

Systemic vasculitides, an introduction.- Standard therapeutic regimens for vasculitis.- Tumor necrosis factor (TNF) inhibition in the treatment of vasculitis.- Methotrexate as an alternative to classic immunosuppressive therapies.- Intravenous immunoglobulin as immuno-modifying treatment.- T-cell directed treatment: anti-thymocyte globulin.- New immunosuppressants: mycophenolate mofetil and 15-deoxyspergualin.- Interferon-? for the treatment of virus-related systemic vasculitides.- Autologous stem cell therapy for systemic vasculitis.- Prevention of relapsing disease in anti-neutrophil cytoplasmic antibody related necrotizing small-vessel vasculitis: the role for autoantibody guided and anti-bacterial treatment.